packageBriakinumab

briakinumab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Briakinumab, a monoclonal antibody that blocks interleukin signalling, was investigated as a treatment for psoriasis. It was never marketed; the marketing application in the European Union was withdrawn, and it remains an investigational drug.

Summary written by glm-5.3-flash from Wikidata Q3644426 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:briakinumab
ATC codes:L04AC09
DrugBank:DB05459
Wikidata:Q3644426
molar mass:146500 g/mol (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown